Scarica l'app Stockscreener
111.86
0.41%
0.35
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Gilead Sciences Lands First FDA Approval of a Twice-a-Year HIV PrEP Drug - MedCity News
US FDA approves Gilead's twice-yearly injection for HIV prevention - Deccan Herald
US approves Gilead’s twice-yearly injection to prevent HIV - The Malaysian Reserve
US approves Gilead's twice-yearly injection to prevent HIV - El Paso Inc.
The world's only twice-a-year shot to prevent HIV could stop transmission — if people can get it - Shelton Herald
Gilead Sciences facility video - KTIV
HIV prevention drug lenacapavir approved by FDA as twice-yearly injection - CBS News
FDA approves Gilead's twice-yearly HIV prevention shot - FirstWord Pharma
Gilead Wins Historic Approval for Twice-Yearly HIV Drug - BioSpace
HIV advance: Twice-yearly shot to prevent infection - NZ Herald
Cautious Optimism for Gilead Sciences Amid Yeztugo’s Market Challenges - TipRanks
Gilead's twice-yearly PrEP drug is cleared by FDA - pharmaphorum
FDA approves twice-yearly shot of Gilead drug for HIV prevention - BioPharma Dive
Gilead's HIV Prevention Drug Is 99.9% Effective. Could Politics Derail It? - Investor's Business Daily
US Approves Gilead's Twice-yearly Injection To Prevent HIV - Barron's
FDA Approves Gilead’s Twice-Yearly Injection for HIV Prevention - The Well News
FDA approves 6-month HIV prevention shot - The Hill
Gilead's (GILD) HIV Treatment Yeztugo Gains FDA Approval, Market Potential Expands | GILD Stock News - GuruFocus
FDA Approval Boosts Gilead's (GILD) Prospects in HIV Prevention | GILD Stock News - GuruFocus
Gilead Sciences stock steady as FDA approves twice-yearly HIV prevention - Investing.com UK
Mizuho says Gilead Yeztugo label looks clean - TipRanks
Gilead Sciences (GILD) Gains FDA Nod for HIV Prevention Drug - GuruFocus
FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time. - Barron's
Gilead Sciences’ Yeztugo Approval and Market Expansion Drive Buy Rating - TipRanks
FDA approves powerful HIV prevention drug: What to know about Yeztugo - NBC News
FDA approves the world’s only twice-a-year shot to prevent HIV - mypanhandle.com
FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV Prevention - ContagionLive
Gilead’s twice-yearly PrEP injection wins FDA approval, analysts see solid launch ahead - Proactive financial news
Gilead Sciences' HIV Prevention Drug Yeztugo Receives FDA Approval - MarketScreener
Gilead (GILD) Gains FDA Approval for Unique HIV Prevention Drug Yeztugo | GILD Stock News - GuruFocus
Gilead announces FDA approves Yeztugo as twice-a-year HIV prevention option - TipRanks
Gilead’s Twice-a-Year HIV Prevention Shot Wins US FDA Approval - Bloomberg.com
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection - marketscreener.com
Gilead's (GILD) Lenacapavir Advances as HIV Prevention Treatment - GuruFocus
Gilead (GILD) Gains FDA Approval for HIV Prevention Injection | - GuruFocus
Gilead’s twice-yearly HIV prevention shot gets FDA approval - Investing.com Australia
US FDA approves Gilead’s twice-yearly injection for HIV prevention By Reuters - Investing.com
Gilead’s twice-yearly HIV prevention shot gets FDA approval By Investing.com - Investing.com Canada
Gilead stock gains on FDA nod for HIV PrEP drug (GILD:NASDAQ) - Seeking Alpha
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option - CNBC
Gilead won U.S. approval for HIV prevention shot, but when will low-income countries gain sufficient access? - STAT
FDA Says Gilead's Yeztugo Receives FDA Approval For HIV Prevention - marketscreener.com
Gilead Researcher Awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award - CSRwire
Buy, Sell, Or Hold GILD Stock? - Trefis
Gilead Sciences, Inc. (GILD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Fibrotic Diseases Treatment Market Top Companies StudyAbbVie - openPR.com
Gilead's HIV drug could end epidemic, but the company has a dark side - Fast Company
Insider Sell: Andrew Dickinson Sells 2,500 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: ReportGilead Sciences (NASDAQ:GILD) - Benzinga
Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern - Insider Monkey
Levi & Korsinsky Investigates Gilead Sciences, Inc. (GILD) Over Possible Securities Fraud - ACCESS Newswire
GILD ALERT: Levi & Korsinsky Investigates Gilead Sciences, Inc. on Behalf of Shareholders Who Lost Money - ACCESS Newswire
Gilead lays off 36 people after axing Oceanside expansion plan - Fierce Biotech
Gilead Sciences: Strong HIV Market Position and Diversified Growth Strategy Justify Buy Rating - TipRanks
Levi & Korsinsky Investigates Possible Securities Fraud by Gilead Sciences, Inc. (GILD) - ACCESS Newswire
Goldman Sachs Reiterates a Hold Rating on Gilead Sciences (GILD) - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Gilead Sciences, Inc. (GILD) Investors to Inquire about Securities Investigation - ACCESS Newswire
Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline (NASDAQ:GILD) - Seeking Alpha
RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey - Insider Monkey
Gilead Stock Drops After FDA Halts HIV Treatment Trials Over Safety Concerns - Daily Chhattisgarh News
Gilead (GILD) Stock Dips in Trading, But 72% Yearly Gain Highlights Powerful Uptrend - Daily Chhattisgarh News
0.45%
1.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):